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Abstract 
BMP2 INDUCED OSTEOGENIC DIFFERENTIATION OF HUMAN UMBILICAL CORD 
STEM CELLS IN A PEPTIDE-BASED HYDROGEL SCAFFOLD. 
 
DEGREE DATE: DECEMBER 12, 2014 
SHRUTHI M. LAKSHMANA, B.D.S, D.M.D. 
COLLEGE OF DENTAL MEDICINE NOVA SOUTHEASTERN UNIVERSITY 
Directed By: Dr. Umadevi Kandalam, Assistant Professor, Department of Pediatric 
Dentistry, NSU College of Dental Medicine. 
 
Craniofacial tissue loss due to traumatic injuries and congenital defects is a major 
clinical problem around the world. Cleft palate is the second most common congenital 
malformation in the United States occurring with an incidence of 1 in 700. Some of the 
problems associated with this defect are feeding difficulties, speech abnormalities and 
dentofacial anomalies. Current treatment protocol offers repeated surgeries with 
extended healing time. Our long-term goal is to regenerate bone in the palatal region 
using tissue-engineering approaches. Bone tissue engineering utilizes osteogenic cells, 
osteoconductive scaffolds and osteoinductive signals. Mesenchymal stem cells derived 
from human umbilical cord (HUMSCs) are highly proliferative with the ability to 
differentiate into osteogenic precursor cells. The primary objective of the study was to 
characterize HUMSCs and culture them in a 3D hydrogel scaffold and investigate their 
osteogenic potential. PuraMatrixTM is an injectable 3D nanofiber scaffold capable of self-
assembly when exposed to physiologic conditions. Our second objective was to 
  
 
 
	  
viii 
investigate the effect of Bone Morphogenic Protein 2 (BMP2) in enhancing the 
osteogenic differentiation of HUMSCs encapsulated in PuraMatrixTM. We isolated cells 
isolated from Wharton’s Jelly region of the umbilical cord obtained from NDRI (New 
York, NY). Isolated cells satisfied the minimal criteria for mesenchymal stem cells 
(MSCs) as defined by International Society of Cell Therapy in terms of plastic 
adherence, fibroblastic phenotype, surface marker expression and osteogenic 
differentiation. Flow Cytometry analysis showed that cells were positive for CD73, CD90 
and CD105 while negative for hematopoietic marker CD34. Alkaline phosphatase 
activity (ALP) of HUMSCs showed peak activity at 2 weeks (p<0.05).   
Cells were encapsulated in 0.2% PuraMatrixTM at cell densities of 10x104, 20x104, 
40x104 and 80x104. Cell viability with WST and proliferation with Live-Dead cell assays 
showed viable cells at all cell concentrations (p<0.05). A two- fold upregulation of ALP 
gene was seen for cells encapsulated in PuraMatrixTM with osteogenic medium 
compared to cells in culture medium (p<0.05). HUMSCs encapsulated in PuraMatrixTM 
were treated with BMP2 at doses of 50ng/ml, 100ng/ml and 200ng/ml. A significant 
upregulation of ALP gene in BMP2 treated cells was seen compared to HUMSCs 
treated in osteogenic medium (p<0.05). Peak osteogenic activity was noted at BMP2 
dose of 100ng/ml (p<0.05). We have developed a composite system of HUMSCs, 
PuraMatrixTM and BMP2 for repair of bone defects that is injectable precluding 
additional surgeries. 
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1 CHAPTER 1 INTRODUCTION 
 Cleft Palate 1.1
 
Figure 1-1 Newborn infant with cleft lip and palate. 
Cleft palate is the second most common congenital malformation in United States 
affecting 225,000 children every year1. Cleft palate is defined as a developmental 
defect of the palate characterized by a lack of fusion of the two lateral portions of the 
palate resulting in a communication between the oral cavity and the nasal cavity2. Two 
main regions are involved in palatal clefts, the primary palate- a triangular shaped piece 
of bone that will include the four incisor teeth and secondary palate which makes up 
90% of the hard and soft palates posterior to the primary palate1. Cleft palate babies 
suffer from several problems such as feeding difficulties, speech abnormalities, 
dentofacial anomalies and psychosocial problems3.  
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 Current protocol for Cleft Lip and Palate management 1.2
Numerous efforts have been made to date in order to repair cleft lip and palate defects 
using surgical procedures in combination with bone graft techniques4.  
These surgeries begin as early as few weeks after birth followed by surgeries during 
mixed and permanent dentition as well5.  
Table 1-1 Current surgical protocol for repair of cleft lip and palate. 
Age  Surgical procedures References 
3-6 months Cheiloplasty/Lip repair Farronato et al, 20146 
6 months Soft palate closure Precious et al, 20017 
12 months Gingivoperioplasty Losquadro et al, 20078 
Before 24 months Primary bone grafting Farronato et al, 20146 
Late mixed dentition Secondary bone grafting Jeyaraj, 20149 
 Complications of Cleft Lip and Palate repairs 1.3
Although these surgeries (Table1-1) are aimed at reducing the adverse effects on 
maxillofacial growth and development while improving social and psychological 
development of the child, it does present with certain unfavorable effects. Some of 
these complications include wound dehiscence, residual lip and/or nose deformity, 
impaired healing, prolonged period of disability, hypertrophic or keloid scar formation, 
pain, postoperative hemorrhage and death4. These residual deformities often require 
more corrective surgical procedures. 25% of patients treated by standardized clinical 
protocol from infancy through adolescence required orthognathic surgery to correct 
anteroposterior discrepancy of the jaws10. 
 Application of bone grafts in Cleft Lip and Palate patients 1.4
Autologous bone graft remains a gold standard for the repair of this defect, which 
requires large amount of bone graft that may lead to donor site morbidity11. On the 
  
 
 
	  
3 
other hand, allografts present potential risk of infections with additional threat of 
immune response of host tissue towards implant12. All these methods are aimed to 
ease the surgical procedures while improving the clinical outcomes of cleft palate 
treatments, reducing the incidence of scar tissue formation and residual facial 
asymmetry. People perceive cleft lip and palate patients differently, even after 
reparative surgery due to residual asymmetry13. Recent developments in stem cell 
based tissue engineering approaches offer an alternative solution. 
 Tissue Engineering 1.5
 
Tissue engineering involves three basic elements- cells, scaffolds and growth factors. 
Bone tissue engineering involves the above elements with osteogenic stem cells, 
osteoconductive scaffolds and osteoinductive growth factors. Osteogenic tissue 
engineering involves regeneration of bone with stem cells from various sources (Table 
1-2) under different culture conditions. Osteogenic tissue engineering plays a crucial 
role in the repair and regeneration of tissue in craniofacial defects. 
Cells	  
Growth	  Factors	  Scaffolds	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 Mesenchymal Stem Cells 1.6
Mesenchymal stem cells are adult stem cells capable of giving rise to tissues of 
mesodermal origin1. MSCs are originally derived from neural crest cells. During 
embryological development cells from dorsal part of neural tube (neural crest cells), 
migrate and form frontonasal processes, first, second, third and fourth pharyngeal 
arches. Neural crest cells contribute to neural, dermal and mesenchymal structures14. 
Mesenchymal cells derived from neural crest cells, after birth, are called “ 
Mesenchymal stem cells” (MSCs)15. 
 
Figure 1-2 Mesenchymal stem cell isolated from Human Umbilical Cord. 
Table 1-2 Source of mesenchymal stem cells in tissue engineering. 
Author Source  
Warotayanont et al, 2009 Embryonic stem cells- inner cell mass16 
Peng et al, 2004 Muscle derived17 
Friedenstein et al, 1968 Bone marrow18 
Covas et al, 2003 Umbilical Cord19 
Rodbell et al, 1964 Adipose tissue15 
Gronthos et al, 2000 Dental Pulp stem cells20 
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Autologous mesenchymal stem cells are cornerstone cells most often used in many 
tissue-engineering applications. Additionally, they appear to be the best choice 
because of the minimal risks associated with immune-rejection in the host21-24. MSCs 
as a cell source for craniofacial tissue engineering, have widely been used in repair and 
regeneration of tissue in the past few years25. The MSCs are undifferentiated cells with 
high proliferation rate, capable of giving rise to diverse tissues including bone, cartilage 
and other tissues of mesenchymal in origin26.  
The purpose of present study was to develop an injectable cell- scaffold system for 
regenerate missing bone in the palatal region.  
Table 1-3 Clinical applications of MSC for osteogenesis. 
Source of MSCs Clinical application of MSC for osteogenesis Author 
Bone marrow Treatment of bone defects with bone aspirate Jager et al, 
200927 
Bone marrow Treatment of long bone defects with culture-expanded 
osteoprogenitor cells and HA scaffolds 
Marcacci et al, 
200728 
Bone marrow Treatment of non-unions with culture expanded marrow cells with 
macroporous HA scaffolds 
Quarto et al, 
200129 
Bone marrow Treatment of tumor defect with culture expanded cells in HA 
scaffold 
Morishita et al, 
200630 
Bone marrow Jaw rehabilitation with BMP7 and MSCs in HA blocks Warnke et al, 
200431 
Allogeneic bone 
marrow 
Treatment of osteogenesis imperfecta with allogeneic MSCs Horwitz et al, 
200232 
Bone marrow Treatment of osteonecrosis with autologous bone marrow grafts Hernigou et al, 
200233 
Adipose tissue Treatment of osteonecrosis in femoral heads with adipose tissue 
MSCs, hyaluronic acid, PRP and calcium chloride 
Pak et al, 
201134 
Bone marrow Treatment of steroid induced osteonecrosis with cultured MSCs in  
β-TCP ceramic 
Kawate et al, 
200635 
Bone marrow Bone marrow derived stem cells and PRP in areas of distraction 
osteogenesis 
Kitoh et al, 
200436 
Bone marrow Bone marrow stem cells in β-TCP scaffold in spinal fusion treatment Gan et al, 
200837 
HA: Hydroxyapatite, PRP: Platelet rich plasma, β-TCP- beta tricalcium phosphate 
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 Human Umbilical Cord Derived mesenchymal Stem Cells 1.7
Human umbilical cord derived mesenchymal stem cells (HUMSCs) are highly 
advantageous potential source for cell-based therapies as umbilical cord can be 
obtained as postnatal tissue that is usually discarded after birth38. Collection of tissue is 
not an invasive procedure and these cells have a high proliferative capacity39. They 
possess self-renewal and have multilineage differentiation potential40,41. The UC 
contains two arteries and one vein, surrounded by a mucoid connective tissue known 
as Wharton’s jelly42 (Figure 1-3). HUMSCs are pluripotent, indicating their ability to 
differentiate into ectodermal, mesodermal or endodermal origin42. HUMSCs possess 
properties of embryonic stem cells and mesenchymal cells42,43. Retaining properties of 
embryonic stem cells, HUMSCs promise a unique ability of stemness (undifferentiated 
nature of stem cells) with a potential to evolve into MSCs that have the potential for 
self-renewal and ability to differentiate into multiple mesenchymal lineages such as 
adipocytes, chondrocytes and osteocytes42. HUMSCs have been used as an 
autologous source of cells for regenerating a wide variety of tissues of cardiac, 
osteogenic, chondrogenic and adipogenic origins44. 
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Figure 1-3 Cross-Section of Human Umbilical Cord  
 Scaffolds  1.8
In cell-based therapies, choosing an appropriate scaffold to deliver the cells is given 
high priority. Scaffolds that promote cell adhesion; proliferation and migration 
characterized by biocompatible and biomechanical parameters are essential45. 
Specifically, craniofacial bony defects like cleft palate require appropriate bone 
substitute scaffold to fill the 3D anatomical defect. The scaffold should have the 
capacity to carry, deliver and house the cells. Additionally, it should provide a 
temporary load bearing capacity until the bone is formed46. Hydrogel scaffolds are able 
to mimic natural extracellular matrix of many tissues and are able to form solid 
constructs that permit homogenous distribution of the cell47. Hydrogels offer the 
convenience of incorporating growth factors and cells prior to injection into the in vivo 
site to enable gel formation48. Injectable hydrogels present a novel approach of cell 
delivery in tissue engineering enabling surgeons to transplant cells in a minimally 
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invasive way49. They are naturally biocompatible, as they do not cause an immune 
response or inflammatory reaction50,51. These gels are degraded by hydrolysis, action 
of enzymes and/or dissolution51. Efficient palatal repair and reduced facial growth 
distortions in cleft palate patients using hydrogels has been achieved25. Self-
assembling peptides are a new class of molecules with the ability to form stable 
hydrogels and have been used in-vivo animal studies for repairing bony defects25,52. 
Cleft palate defects are irregular and are 3 dimensional. Consequently, a 3D scaffold 
that mimics the defect while being rigid enough to support cells and flexible to blend 
into host tissue would be ideal. 3D scaffolds increase cell proliferation, migration and 
viability compared to preformed 2D scaffolds45. Our study intends to use a 3D peptide 
based hydrogel biomaterial, PuraMatrix, with over 99% water content that can self- 
assemble into 3D interweaving nanofibres53.  
 PuraMatrixTM 1.9
PuraMatrixTM is a liquid self-assembling peptide scaffold that became commercially 
available in 200154. They are also called self-assembling peptide nanofiber scaffolds 
(SAPNS) and RADA peptides because of its component Arginine, Aspartic acid and 
Alanine residues. Under physiologic salt conditions they are known to form 
nanostructured fibrillar hydrogels53. Nanostructured biomaterials are gaining popularity 
in regenerative medicine because they mimic natural extracellular matrix in a nano 
scale55. Physical and biological parameters of this scaffold can be modified due to its 
synthetic nature. Bioactive modifications can be made, which makes it versatile in 
terms of cell adhesion while increasing its stability56. PuraMatrixTM hydrogel is capable 
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of both ionic and hydrophobic interactions54. These interactions trigger spontaneous 
self-assembly enabling cell encapsulation and filling in both in vitro and in vivo 
applications. We intend to use this property to encapsulate HUMSCs within the 
PuraMatrixTM for the purpose of site-specific delivery of cells and growth factors.  
 Bone Morphogenic Proteins 1.10
Bone morphogenetic proteins are a family of osteoinductive proteins that promote 
differentiation of mesenchymal cells into osteoblasts and promote neovascularization57. 
Among the 15 identified BMPs, BMP-2 and BMP-7 (i.e., osteogenic protein-1) are now 
commercially available and have been investigated as an alternative to bone auto 
grafting in a variety of clinical situations, including spinal fusions, internal fixation of 
fractures, treatment of bone defects, and reconstruction of maxillofacial conditions58-62. 
While BMP2 is used widely in many applications, adverse effects such as enhanced 
bone formation in undesired site63, inflammation64 and respiratory distress65 have been 
reported. The conventional use of BMPs for therapeutic applications is to administer 
large quantities66. However, minimal and optimal dosage is essential when it is used for 
pediatric population. Keeping this in view, the project is intended to investigate an 
optimal dosage of use of BMP2 while developing a cell based composite scaffold 
system. In- vitro studies report-using doses of BMP2 ranging from 100- 400ng/ml for 
osteogenic differentiation with mesenchymal stem cells as cell source67. Doses as low 
as 0.1ng/ml and as high as 1000ng/ml have been used for osteogenic differentiation of 
Human Marrow Stromal Precursor Cells68. HUMSCs have been used for osteogenic 
differentiation using osteogenic medium, however, they have not been used in 
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combination with BMP269. The aim of this study is to find an optimum dose of BMP2 
that can be used for osteogenic differentiation of HUMSCs with PuramatrixTM as a 
scaffold system. 
 Focus of our research 1.11
The current protocol for repair of cleft lip/palate defects involves multiple surgeries to 
correct both hard and soft tissue defects4. Numerous efforts are being made to reduce 
the incidence of surgical procedures and develop procedures aimed at tissue self-
renewal and regeneration51. Cell based therapies involving osteoinductive growth 
factors and biocompatible scaffolds with stem cells offer great promise70.  
Innovation: This study intends to develop a novel procedure using PuraMatrixTM, a 
new biomaterial that helps serve as synthetic extracellular matrix to support growth and 
differentiation of cells. This hydrogel scaffold helps organize cells in a 3D architecture 
and enhances osteogenic differentiation. Our study uses a composite system of 
HUMSCs as source cells, PuraMatrixTM as an injectable scaffold in combination with 
BMP2 as a growth factor. This combination has never been investigated before. 
Published studies report the use of BMP2 ranging from 100ng/ml to 400ng/ml for 
osteogenic differentiation of MSCs67. Previous literature has reported adverse effects 
when BMP2 is used clinically. Our aim is to determine an optimum dose of BMP2 for 
the purpose of osteogenic differentiation in young patients with cleft lip/palate and this 
in-vitro study is the pioneering step in developing an in-vivo procedure.  
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 Objectives 1.12
The long-term goal of this project is to develop a 3D injectable scaffold for the purpose 
of bone regeneration in patients with cleft lip and palate defects using HUMSCs and 
minimal dose of BMP2. 
 Specific aims and Hypothesis 1.13
1.13.1 Specific Aim #1: Encapsulating HUMSCs in PuraMatrix  
The first aim of this study was to investigate the capability of PuraMatrixTM, a 3D self-
assembled peptide-based hydrogel, to support osteogenic differentiation of human 
umbilical cord derived mesenchymal stem cells (HUMSCs). 
1.13.2 Specific Aim #2:  Effect of BMP2 on Osteogenic  differentiation of 
PuraMatrixTM encapsulated HUMSCs 
The second aim of this study was to assess the effect of different does of BMP2 on 
osteogenic differentiation of PuraMatrixTM encapsulated HUMSCs. 
1.13.3 Hypothesis 
Null Hypothesis Specific Aim 1: PuraMatrixTM does not support osteogenic 
differentiation of HUMSCs. 
Alternative Hypothesis Specific Aim 1: PuraMatrixTM supports osteogenic 
differentiation of HUMSCs. 
Null Hypothesis Specific Aim 2: Low doses of BMP2 do not enhance osteogenic 
differentiation of HUMSCs. 
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Alternative Hypothesis Specific Aim 2: Low doses of BMP2 enhance osteogenic 
differentiation of BMP2. 
 Location of Study 1.14
This study was conducted in Craniofacial Research Center (Room #7391), College of 
Dental Medicine Nova Southeastern University, Fort Lauderdale, FL 33328. 
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2 CHAPTER 2 MATERIALS AND METHODS 
 Materials 2.1
Human umbilical cord was obtained from NDRI (National Disease Research 
Interchange, Philadelphia, PA) after Nova Southeastern University’s Institutional 
Review Board approval. Commercially available PuraMatrix™ hydrogel BD 
Biosciences, San Jose, CA) was used for the study. Mesenchymal stem cell medium 
was obtained from Sciencell (Carlsbad, CA). Commercially available rhBMP2 (R&D 
systems, Minneapolis, MN) was used. All other necessary chemicals and lab supplies 
were obtained from Sigma (St. Louis, MO) and VWR international (Atlanta, GA), 
respectively. 
 Overall study design 2.2
Human umbilical cord tissue was obtained from National Disease Research 
Interchange (NDRI; Philadelphia, PA). HUMSCs were isolated from umbilical cord 
using explant method. The detailed procedure is discussed in section 2.3.2. Cells 
isolated from the tissue were cultured and expanded under standard culture conditions. 
Cells at 70-80% confluency were induced with osteogenic supplements and osteogenic 
differentiation of HUMSCs was determined by gene expression of various osteogenic 
differentiation marker genes. Mineral deposition of osteogenically induced cells was 
confirmed by Alizarin Red and Von kossa staining techniques. Cells were encapsulated 
in 3D PuraMatrixTM scaffold and then supplied with CM in one group and OM in other 
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group. Cells were encapsulated in PuraMatrixTM in different cell concentrations (1x104, 
2x104, 4x104 and 8x104 cells/ml). Cell viability was assessed by using live/dead cell 
assay. Cell proliferation was assessed by WST assay. Cells were encapsulated in 
PuraMatrixTM with different concentrations of BMP2 (50ng/ml, 100ng/ml, 200ng/ml) for 1 
week. Cells grown in osteogenic medium served as a control. Osteogenesis was 
determined by gene expression studies, mineralization studies and ALP assay.  
 Isolation protocol 2.3
In this study, we employed both Explant culture and Enzymatic digestion methods for 
isolating cells from human umbilical cord. 
2.3.1 Ethics Statement  
This study was conducted in accordance with Nova Southeastern University’s 
institutional review board guidelines to obtain human umbilical cord from NDRI 
(Philadelphia, PA). Once umbilical cord was obtained, isolation procedure was carried 
out within 48 hours after collection. We have primarily used explant method to isolate 
cells from tissue. 
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2.3.2 Explant method 
 
Figure 2-1 Isolation protocol with Explant method. A- Section of Umbilical Cord 
before longitudinal incision. B- Removal of vessels from the umbilical cord. C- 
Explant tissue in culture medium, D- Vessels removed from umbilical cord tissue. 
 
Umbilical cord was cut into 5 cm sections. Umbilical cord was washed with sterile 
phosphate buffer saline (PBS) to remove blood71. A longitudinal section was made into 
the umbilical cord parallel to the umbilical vein to enable visualization of the vessels 
before removal. Umbilical vessels- 2 umbilical arteries and 1 umbilical vein were 
dissected and removed completely. 5 cm sections of umbilical cord were placed in a 10 
cm2 petridish with 5 ml of culture medium (CM-DMEM supplemented with 10% FBS 
and 1% antibiotics) and incubated at 370 C with 5% CO2. Culture medium was changed 
every three days. After 5 days, cells were found attached to the surface of the petridish. 
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Sections of the umbilical cord were discarded and fresh culture medium was added. 
The cells were then expanded until they reached 70-80% confluence with medium 
changed twice every week.  
2.3.3 Enzymatic Digestion 
 
Figure 2-2 Isolation of HUMSCs using Enzymatic Digestion. 
After removal of umbilical vessels, umbilical cord was cut into pieces each measuring 
approximately 2 cms. Tissue was washed with PBS. The tissue was further minced and 
kept for digestion in 0.1mg per ml type I collagenase and 2mg/ml dispase at 37ᵒ C with 
continuous shaking for one hour. Cell suspension with enzyme solution was collected 
and enzyme digestion was continued for the remaining tissues.  The cell suspensions 
were pooled and centrifuged at 900 rpm for 10 minutes.  The supernatant was 
discarded and the pellet was suspended in culture medium (Dulbecco’s Modified 
Eagles medium- DMEM, Fetal Bovine Serum- FBS, Penicillin 1%, Streptomycin 1%) 
and cultured for further expansion in a 370C humidified environment with 5% CO272. 
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 Cell Culture 2.4
HUMSCs were cultured in monolayers in T75 flasks with Mesenchymal Stem Cell 
Medium (MSCM). The cells were fed with fresh medium every 2-3 days. Cultures were 
propagated at 37 °C under humidified conditions using 5% CO2. Cells with 70-80% 
confluency were treated with trypsin to dislodge from the flask and plated again until 3rd 
passage. Cells from passage 3 or 4 were used in this study. 
  
Figure 2-3 Incubator, B and C- Cell culture in T75 flask. 
 Characterization of HUMSCs  2.5
In order to verify the mesenchymal origin, HUMSCs must meet several criteria set forth 
by the International Society for Cellular Therapy73. The mesenchymal origin of 
HUMSC’s was confirmed by their plastic adherence, observation of fibroblastic 
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phenotype under light microscope, differentiation capacity to osteogenic lineage in vitro 
and by surface marker expression. 
2.5.1 Flow Cytometry surface marker analysis 
All flow cytometry experiment procedures were performed in University of Miami. 
Passage 3 or Passage 4 cells after attaining sub-confluence were used.  Cells at the 
concentration of 106 cells were used to measure the surface markers using Miltenyi Kit 
according to manufacturer’s instruction. The specific markers positive for mesenchymal 
stem CD73, CD90 and CD105 and negative for CD34 were identified at the facilities at 
University of Miami using a fluorescent activated cell sorter FACAria IIIu (BD 
Biosciences, San Jose, CA) with adjusted florescence compensation setting. Negative 
samples were used to set up the thresholds of quadrant markers.   
2.5.2 Osteogenic Differentiation  
The monolayer cultures were grown in culture medium (CM) consisting of DMEM, 10% 
FBS and 1% antibiotics. The cells at 70-80% confluency were replaced with growth 
medium supplemented with osteogenic reagents, which include 50mM ascorbic acid 
and 10mM of β-glycerophosphate and 100nM dexamethasone. The osteogenic 
differentiation was measured at 1 week, 2 weeks and 3 weeks intervals. Osteogenic 
differentiation potential of HUMSCs was determined by measurement of ALP activity, 
gene expression studies, western blotting and mineralization studies. The osteogenic 
potential of HUMSCS induced with osteogenic medium will be compared with the cells 
grown in CM. 
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2.5.2.1  Alkaline Phosphatase (ALP) Activity Assay 
Cells at 70-80% confluency were trypsinized and plated in 6 well plate at 60X103 cells 
per well. Cells grown with or without osteogenic medium were collected from each well 
at different time points (1, 2 and 3 weeks) and lysed with m-per mammalian protein 
extraction reagent (Thermo Scientific, Rockford, IL). ALP activity was measured by a 
pNPP assay (Sciencell, Carlsbad, CA) according to manufacturer’s instructions. Briefly, 
15µL of cell lysate was placed in a 96 well plate and 35 µL of alkaline reaction buffer 
was added to each well followed by 5µL of pNPP substrate and the cells were 
incubated at 37ᵒC for 30 minutes and pNPP production was measured by a microplate 
reader at 405 nm. The ALP activity of cells grown in OM was compared with cells 
grown in CM.   
2.5.2.2 RNA Isolation, reverse transcription and Polymerase Chain Reaction 
mRNA expression of ALP, Osteoprotegrin, Osteopontin and Collagen Type I was 
measured at 1, 2 and 3 weeks for cells grown with or without osteogenic supplements. 
Cells were cultured in t-25 flasks and total RNA was extracted using TRIzol method 
(Ambion, Carlsbad, CA) (Figure 2-6). RNA was quantified by using smart spec 
spectrophotometer (Bio-Rad, Hercules, CA). RNA was reverse transcribed and cDNA 
was synthesized using high capacity reverse transcriptase kit (Life Technology, 
Carlsbad, CA) according to manufacturer’s instructions. Osteogenic marker genes ALP, 
Osteopontin and Osteoprotegrin were assessed at 7-day interval using Q 
semiquantitative PCR (Biorad, Hercules, CA) using specific primers (Table 2-1).  The 
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PCR products were separated by 2% agarose gel and the relative density was 
measured using a densitometry analysis. 
Table 2-1 Specific Primers Table 
 
2.5.2.3 Mineralization Assays 
Alizarin red and Von Kossa staining was performed in order to analyze matrix 
mineralization. 
2.5.2.4 Alizarin Red Stain 
Cells were plated in a 12 well plate. Osteogenesis was induced on day 3 using OM. A 
quantitative Alizarin red S method was used at the end of 1, 2 and 3 weeks. Briefly the 
cells were fixed with 10% formalin followed by staining with 2% Alizarin red S solution 
(Sigma- Aldrich) for 20 minutes. Cells were photographed under the microscope.  
2.5.2.5  Von Kossa stain 
To determine the presence of phosphate based mineral, cells were stained with 2% 
silver nitrate (Sigma-Aldrich, St Louis, MO) solution for 1 hour under bright light. The 
reaction was stopped by adding the developing solution, viz. 1% sodium thiosulphate 
(Sigma-Aldrich, St Louis, MO) for 1 min. Sections were counterstained with 0.5% 
Gene Sequence 
Col I (sense) 5'-ctgaccttcctgcgcctgatgtcc-3' 
Col I (antisense) 5'-gtctggggcaccaacgtccaaggg-3 
ALP (sense) 5'-ccacgtcttcacatttggtg-3' 
ALP (antisense) 5'-agactgcgcctggtagttgt-3' 
OPN (sense) 5'-tgaaacgagtcagctggatg-3' 
OPN (antisense) 5'-tgaaattcatggctgtggaa-3' 
beta-actin (sense)  5'-catgtacgttgctatccaggc-3' 
beta-actin (antisense)  5'-ctccttaatgtcacgcacgat-3' 
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nuclear fast red (Sigma, Aldrich, St. Louis, MO) and dehydrated in saline and mounted 
with DPX and observed under phase contrast microscope (Olympus, XI 50). 
 Encapsulating HUMSCs in 3D peptide hydrogel scaffold PuraMatrixTM 2.6
PuraMatrixTM from BD Biosciences was assembled using CM following manufacturer 
protocol in a 24 well plate. The cells were suspended in 20% sterile sucrose solution 
that was previously autoclaved. The cells suspended in sucrose solution were 
encapsulated in 0.2% Puramatrix TM. Commercial PuraMatrixTM is available at a 
concentration of 1%. It was further diluted with sucrose solution to prepare 0.2% gel. 
Cell seeding densities were 1x104 HUMSCs in monolayer 2D culture. And increasing 
cell concentrations of 100x103, 200x103, 400x103 and 800x103  were used per well for 
encapsulation in PuraMatrixTM. For Cell viability assays 50µL of PuraMatrixTM was 
used. Cells mixed with 50µL of PuraMatrixTM were slowly dropped into 150µl of culture 
medium. And the cell- gel constructs were incubated in 370C at 5% CO2. 
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Figure 2-4 A- Commercially available PuraMatrixTM, B and C- Injectable hydrogel 
PuraMatrixTM. 
 Cell Viability and Proliferation of HUMSCs in 3D PuraMatrixTM Culture 2.7
In order to assess cell viability and proliferation, WST and Live-Dead assay were 
performed respectively. 
2.7.1 WST Assay 
Cells were encapsulated at 100x103, 200x103, 400x103, 800x103 per well in a 96 well 
plate. 50µL of 0.2% PuraMatrixTM was used per each well. In order to prepare cell-gel 
constructs, 200 µl of growth medium was placed in each well of the plate. Cells 
suspended in 0.2% gel were slowly released into the growth medium. After 30 minutes 
of incubation at 37ᵒC, growth medium was replaced and cells were fed with new growth 
medium and gelation was examined under microscope. Cell proliferation was assessed 
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by addition of WST-1 (2-4-iosophenyl)-3-4-nitrophenyl)-5-(2,4 disulfophenyl)-2H-
tetrazolium, monosodium salt) reagent to a 1:10 final concentration. WST-1 cell 
proliferation assay (Roche, Indianapolis, IN, USA) is a mitochondrial activity assay. 
WST reagent is a soluble tetrazolium salt that can react with metabolically active cells 
and gives a deep red color.  The cell-gel constructs were finally incubated at 370C with 
5% CO2.  The assay was conducted after 72 hours of incubation and the absorbance 
was measured using micro-plate reader (Figure 2-5). The cell viability was measured 
and compared.  
 
Figure 2-5 Cells encapsulated in PuraMatrixTM for WST assay. 
2.7.2 Live Dead Cell Assay 
Cell viability of the HUMSCs in PuraMatrixTM was also confirmed by a Live/Dead cell 
assay (Molecular Probes, Carlsbad, CA). Cells at 100x103, 200x103, 400x103, 800x103 
were encapsulated in 0.2% PuramatrixTM.  Cell proliferation was examined after 72 
hours of incubation using a Live-Dead cell assay kit (Life Technology, Carlsbad, CA) 
according to manufacturer’s protocol. Briefly, the cells encapsulated in PuraMatrixTM gel 
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was washed twice with PBS and Live/Dead cell stain was added.  Live/Dead cell assay 
kit was provided with two molecular probes, calcein AM and ethidium homodimer-1 
(Eth-D). These probes were used for simultaneous visualization of the live cells and 
dead cells. Live cells emit Green Fluorescence, when calcein AM enters the cells and is 
hydrolyzed to calcein by intracellular esterase. Eth-D 1 enters into nucleic acids to 
produce bright red Fluorescence that indicates dead cells. The 2µm ethidium 
homodimer-1 and 2µm calcein AM was reconstituted in PBS. Cells were incubated at 
370C for 30 minutes. Micrographs were then taken using a fluorescent microscope 
(Olympus IX 51) equipped with a digital camera (Olympus XC 30).  
2.7.3  Cell-Gel Constructs - Osteogenic differentiation 
PuraMatrixTM in combination with stem cells can induce osteogenic differentiation in the 
presence of osteogenic supplements74. Medium was replenished every 3-4 days. For 
differentiation assays 24- well plates were used. Cells suspended in 20% of sterile 
sucrose (120 µL) with 80 µL of 1% PuraMatrixTM and dropped slowly into growth 
medium in which the scaffold can self-assemble to acquire gel morphology. The 
gelation was observed under microscope. Gene expression of osteogenic markers was 
investigated using RT-PCR and matrix mineralization was monitored after one week. 
 BMP2 treatment and cell seeding on to scaffolds 2.8
Cells were suspended and were loaded onto the scaffolds as previously described in 
the encapsulation section. Briefly, a total of 2 x 106 cells were seeded in a drop wise 
manner in the PuraMatrixTM solution and the cell-scaffold insert was placed in each well 
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of 24-well culture plates and allowed to solidify. The cells in the scaffold were provided 
with 1ml of culture medium and incubated at 37°C and 5% CO2. Osteogenic medium 
containing increasing concentrations of BMP2 50ng/ml, 100ng/ml and 200ng/ml was 
introduced on the third day. The cell-scaffold inserts were replenished with fresh 
medium every 48 hours. The cell-scaffold insert supplemented with osteogenic medium 
only was considered as control group. Experiments were performed for osteogenic 
induction and mineralization. All experiments were repeated at least three times.  
 
Figure 2-6 BMP2 treatment of cells encapsulated in PuraMatrixTM. 
 Osteogenic Differentiation  2.9
2.9.1 Gene Expression 
Cells were plated in T-25 flasks in culture medium (CM). Osteogenic medium was 
introduced on day 3. Medium was changed twice each week for 2 weeks. Quantitative 
real-time reverse transcription polymerase chain reaction was used to analyze the 
expression of osteogenic genes. Total RNA was isolated from cells at the end of 1 and 
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2 week time-points using RNeasy Mini kit following manufacturer’s instruction. The 
concentration of RNA was determined by spectrophotometer. RNA was reverse 
transcribed and cDNA was synthesized.  Osteogenic marker genes ALP, Osteopontin 
and Osteoprotegrin were assessed at 7-day interval using Quantitative PCR (Step–One 
plus Applied Biosystems, Foster City, CA) using specific primers (Table 2-1). 
Expression levels were determined by using   2-ΔΔCt methods.  
 
Figure 2-7 Steps involved in RNA isolation 
2.9.2 Statistical Analysis 
Data was expressed as mean ± standard deviation (SD) of at least three independent 
samples. Statistical comparisons between groups were performed with a two tailed 
student’s t-test, P< 0.05 was considered as significant. 
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3 CHAPTER 3 RESULTS 
 Characterization of HUMSCs  3.1
Cells were extracted from the Wharton’s jelly region of the umbilical cord using both 
Explant and Enzymatic digestion methods. We preferred the explant method due to 
ease of processing. We obtained more cell yield from the Explant method. Isolated cells 
demonstrated a fibroblast- like phenotype when observed under light microscope 75. 
 
Figure 3-1 A- Cells after plating B- Fibroblastic phenotype of HUMSCs  
The cells obtained from explant culture or enzyme digestion of umbilical cord fragments 
were seeded on to a T75 flask at a density of 0.5 x 106. Fig 3-1 shows cells after 
plating.  After 24 hours the cell morphology was observed under phase contrast 
microscopy. Adherent cells demonstrated typical fibroblast morphology (Fig 3-2). This 
represented the 100% of harvest efficiency. The cells reached confluency 4 days after 
plating. 
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Figure 3-2 A- Cells 2 days after plating, B- Cells at confluence after 4 days 
3.1.1 Immunophenotype of HUMSCs 
For all experiments cells from passage 3 to passage 5 were used. HUMSCs must meet 
certain criteria as defined by the International Society for Cellular Therapy73. 
Mesenchymal origin of HUMSCs in this study was confirmed by their plastic adherence, 
fibroblastic phenotype, surface marker expression and their ability to differentiate into 
osteogenic lineages in-vitro. Flow cytometric analysis of HUMSCs after passage 3 
demonstrated that cells were 90% positive for surface markers CD73, CD90, CD105 
and negative for hematopoietic marker CD34. Results verify the mesenchymal origin of 
HUMSCs and the lack of hematopoietic markers (Figure 3-3). 
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Figure 3-3 Flow Cytometry Data showing surface marker of MSCs 
3.1.2 Osteogenic Differentiation of HUMSCs 
Osteogenic differentiation potential of monolayer HUMSCs was assessed by using 
passage 3 to passage 5 cells. Cells in culture medium (CM) were considered as control 
group and cells in osteogenic medium as experimental group. The osteogenic 
differentiation was monitored at 1, 2 and 3 weeks. Osteogenic differentiation was 
determined by ALP activity assay, gene expression and mineralization studies using 
Alizarin Red and Von Kossa stain.  
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3.1.2.1 ALP activity 
Alkaline phosphatase is an early marker for osteogenic differentiation. Our results 
showed significant increase of ALP activity (15%) at the end of 1 week in OM group 
compared to CM group. There was a significant increase (>45%) in OM group 
compared to control group at 2 weeks. The enhancement of ALP activity of OM group 
was at its peak at day 14 (P=0.027) than at day 7. Although there is significant increase 
in ALP activity when compared to cells grown in culture medium, the cells showed more 
than 30% decrease in ALP activity at the end of 3 weeks.  
 
Figure 3-4 ALP activity of HUMSCs in CM compared to OM samples at 1,2 and 3 
weeks. 
3.1.2.2 Gene Expression 
Gene expression of osteogenic lineage was assessed by semi quantitative PCR. 
Osteoblast specific genes Alkaline phosphatase (ALP), Osteoprotegrin (OPG), 
Collagen type I (Col1), Osteopontin (OPN) were assessed at 1, 2 and 3 weeks 
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intervals. B actin served as endogenous control. The results indicated that ALP gene 
expression upregulated at 1 and 2 weeks. The peak up regulation was observed at 14th 
day. On the other hand, Collagen type I started up regulating from week 1 and 
continued until 3 weeks. 
 
Figure 3-5 Gene expression showing upregulation of osteogenic genes ALP, 
OPG, Col I and OPN. B-Actin was used as an endogenous control. 
3.1.2.3 Mineralization studies with Alizarin Red and Von Kossa stains 
Matrix mineralization with calcium and phosphate is a late indicator of osteogenesis 
and maturation of osteoblasts. Calcium deposits were discerned using Alizarin Red 
stain. There was a significant increase in calcium deposits at the end of 3 weeks for 
cells in OM compared to cells in control group with CM. Matrix mineralization for 
phosphate deposits was determined by von Kossa staining technique. 
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Figure 3-6 A- Alizarin red staining in CM after 4 weeks. B- Alizarin red staining in 
OM after 4 weeks. 
 
 
Figure 3-7 Von Kossa Staining of cells, A- Cells in control group CM at 4 weeks, 
B- Cells in OM at 4 weeks, B- Cells in OM at 8 weeks. 
 Cell morphology of cells encapsulated in PuraMatrixTM 3.2
Hydrogels containing HUMSCs were observed under phase contrast view of Olympus 
IX 51 (Center Valley, PA). Figure 3-8 A shows cells encapsulated in PuraMatrixTM. Cells 
were spherical immediately after encapsulation and cell growth was observed within 24 
hours. The cells attained spindle shaped after 24 hours (Fig 3-8 B). On day 3, cells 
started forming a network (Fig 3-9 A). At higher concentrations, cell aggregate 
formation was observed in PuraMatrixTM gels (Fig 3-10). Cell survival and proliferation 
was examined by WST assay and Live Dead Cell assay. 
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Figure 3-8 A- 100K cells in PuraMatrixTM on Day 0, B- 100K cells in PuraMatrixTM 
on Day 1. 
 
Figure 3-9 A- 100K cells in PuraMatrixTM on day 3, B- 100K cells in PuraMatrixTM 
on day 4 showing cellular interconnections. 
 
 
!
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Figure 3-10 800K cells in PuraMatrixTM on day 10. 
 Cell proliferation and viability in PuraMatrixTM 3.3
WST and Live- Dead Assay as described below assessed cell proliferation and viability. 
3.3.1 WST assay 
Cell proliferation was observed by seeding cells in different concentrations. Cells were 
encapsulated at a density from 100x103 to 800x103 cells per well in a 96 well plate. Cell 
proliferation was assessed after 72-hour time point. Cells survived at all concentrations, 
however, survival rate was higher at 100 x103 and 200x103. There was slight decrease 
in cell viability of cells with increase in cell number (Fig 3-11).  
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Figure 3-11 Cell proliferation with WST Assay. 
3.3.2 Live dead cell assay 
The results of live dead cell assay demonstrated that cells were viable at all 
concentrations at 72 hours. The cells encapsulated at higher densities showed 
clustered structures. Figure 3-12 to 3-14 show cells at various densities. Cells at all 
concentrations showed a typical spindle shaped structure 3 days post seeding.  Overall 
results demonstrated that cells are viable at all concentrations. 
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Figure 3-12 A- Live cells in PuraMatrixTM at 100K concentration, B- Live cells in 
PuraMatrixTM at 100K concentration. 
 
 
Figure 3-13 Live cells in PuraMatrixTM at 400K concentration, inset picture shows 
cells growth in PuraMatrixTM gel. 
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Figure 3-14 A- Live cells in PuraMatrixTM at 800K concentration, B- Cells in 
PuraMatrixTM at 800K concentration displaying 1 dead cell. 
 
 Osteogenic differentiation of cells in PuraMatrixTM 3.4
Osteogenic differentiation of cells was determined by ALP gene expression as 
described below. 
3.4.1 Gene expression 
Gene Expression was monitored during the crucial early period of osteogenic 
differentiation. A cell seeding density of 8x105 in 200µL gel in a 24 well plate was used. 
ALP gene expression of cell-gel constructs grown in osteogenic medium was compared 
with cell-gel constructs in culture medium on day 7 using Quantitative PCR method. 
ALP expression showed a 2-fold upregulation in OM cell-gel constructs compared to 
cell-gel constructs in culture medium used as control.   
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Figure 3-15 2-fold upregulation of ALP gene in cell-gel constructs in OM. 
 Effect of BMP2 on HUMSCS encapsulated in PuraMatrixTM 3.5
Cell-gel constructs induced with increasing concentration of BMP2 were compared with 
cell-gel constructs in osteogenic medium. Cell- gel constructs in osteogenic medium 
were considered as control. The mRNA expression of ALP displayed gradual 
upregulation with increasing concentration. A 2-fold enhancement in ALP mRNA 
expression was evident at 100ng/ml of BMP2. However, there was a gradual decrease 
at 200ng/ml. A significant upregulation was noted at all concentrations of BMP2 
compared to cell-gel constructs induced with osteogenic medium alone.   
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Figure 3-16 Significant expression of ALP gene in BMP2 induced cell-gel 
constructs compared to cell-gel constructs in OM. 
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4 CHAPTER 4 DISCUSSION AND CONCLUSIONS 
 Discussion 4.1
Current procedures for the repair of critical size bone defects such as cleft palate rely 
on various bone grafting methods. Emergence of stem cell based tissue engineering 
strategies is recognized as a promising source to regenerate biological tissue 
substitutes for critical size bony defects76-78. The objective of the proposed study was to 
develop an injectable cell-growth factor-scaffold system for repair of bony defects. In 
this study, HUMSCs were used as cell source, commercially available hydrogel, 
PuramatrixTM, was used as a scaffold and growth factor BMP2 was utilized as 
osteogenic inducer. First part of this study focused on the isolation and characterization 
of HUMSCs. Furthermore, HUMSCs were cultured in a 3-dimensional peptide scaffold 
and investigated for their osteogenic differentiation. 
Human umbilical cord is a potential source of mesenchymal stem cells (MSCs) that are 
developmentally primitive, highly proliferative with potential to differentiate along 
mesenchymal lineages22,79. Recent evidence demonstrated their potential to form 
bone80. Isolation of MSCs from distinct parts of the umbilical cord and use of different 
methods for isolation has been reported38,44,81-83.  In this study, we have isolated MSCs 
from Wharton’s Jelly region using two different methods - explant culture and enzymatic 
digestion. In explant cultures, the cells aroused from the tissue after one week and 
were confluent within 10 days.  Enzymatic digestion resulted in successful isolation; 
nevertheless, the cell yield was low when compared with explant culture in our study. In 
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contrast, many authors have reported a high yield of cells after enzymatic digestion84. 
The low yield may be due to inappropriate digestion. Isolated cells exhibited fibroblastic 
morphology. Furthermore, isolated HUMSCs satisfied the criteria set forth by the 
International Society for Cellular Therapy in terms of plastic adherence, fibroblastic 
phenotype and differentiation into osteoblastic lineage. Immunophenotyping involves 
the detection of surface antigen on cells. The flow cytometry results revealed that they 
were positive for CD73, CD105, CD90 and negative for CD34. CD73, CD105 and CD90 
are specific for mesenchymal cells73. In agreement with other studies, we found that 
90% cells exhibited mesenchymal stem cell property.   
In this study, HUMSCs obtained from passage 3 to 5 were used for all experiments. 
Researchers have reported that early passage cultures are needed to conduct the 
preclinical study as the MSCs gradually lose their proliferation capacity after several 
passages22. The advantages of using HUMSCs include their rapid proliferation rate and 
ability to expand over 7 passages without losing differentiation potential69. 
Mesenchymal stem cells are able to differentiate into osteoblasts under appropriate 
stimuli. Several genes and proteins are upregulated during osteogenic differentiation. 
Of the several osteogenic markers, most remarkable ones are ALP, Osteopontin, 
Osteocalcin and Collagen type I. Several assays such as ALP activity, gene expression 
and mineralization studies were conducted to detect osteogenic differentiation in the 
current study.  ALP activity assay is a commonly accepted biochemical marker assay 
for osteogenic differentiation. ALP is a metalloenzyme that is tissue specific encoded by 
separate genes85. ALP is important for hard tissue formation because it increases the 
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local concentration of inorganic phosphates, a phenomenon postulated as the ‘booster 
hypothesis.’86 ALP expression marks the success of osteogenesis because it inevitably 
leads to the formation of mineralization87,88. ALP activity in cells is primarily low but as 
osteogenic differentiation progresses; the progenitor cells undergo differentiation 
towards matrix maturation. ALP activity continues to increase during this process and 
finally decreases when osteoblasts turn into osteocytes89-91. Our results demonstrate 
similar pattern, the levels of ALP increased gradually with maximum increase on day 14 
and a significant decrease on day 21. Gene expressions of ALP, Collagen type 1 and 
Osteopontin (OPN) were significantly increased at all-time points (1, 2 and 3 weeks) as 
well. Furthermore, HUMSCs have demonstrated ability to differentiate along osteogenic 
lineages which was confirmed by Von Kossa and Alizarin red staining 
In this study, commercially available hydrogel scaffold PuraMatrixTM was used to 
encapsulate HUMSCs. PuraMatrixTM is a peptide hydrogel that has been used for 
multiple applications ranging from bone, cartilage92, vascular93, neural94 to dental pulp 
tissue engineering74. It’s unique features of self-assembly, injectability, nanofibre 
structure enables the cell attachment, migration and permeation of nutrients95,96,97. 
These properties of the scaffold can minimize surgical procedures and reduce scar 
formation98.  
Data from WST and Live-Dead cell assay showed that HUMSCs encapsulated in 
PuraMatrixTM survived at all cell density ranges. However, cells at 200x103 was the 
most suitable concentration. Although, there was no statistically significant decrease, 
there was a decrease in the cell number as observed at 400 - 800x103 cells. Our 
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results are in agreement with the results of Cavalcanti et al74. Growth of dental pulp 
derived stem cells stopped at 800x 103 in this study74, on the other hand, our results 
show approximately 1% cell death 10 days after seeding. However, cells were able to 
migrate within the gel while maintaining spindle shaped structure with network 
formation. Our results indicate that 0.2% PuraMatrixTM is ideal concentration for cell 
encapsulation and growth. Previously it has been reported that 1% PuraMatrixTM forms 
a mechanically stable gel, nevertheless it was not suitable for cell survival74. Ability of 
osteogenic differentiation of cells encapsulated in PuraMatrixTM was investigated in this 
study. Cells encapsulated in PuraMatrixTM   grown in culture medium (CM) were 
compared with the cells encapsulated in PuraMatrixTM induced with osteogenic 
differentiation medium (OM). Within one week of induction, a significant increase of 
over 2-fold was elicited for cells in OM compared to cells in CM.  Chen J et al reported 
a periodic increase in the ALP gene expression99. The limitation of our study is a lack of 
data on comparison of osteogenic potential of 2D cultures compared to cells in 
PuraMatrixTM in complete medium.  
The second part of this study focused on optimizing growth factor concentration. In 
bone tissue engineering strategies, growth factor remains one of the important 
components.   
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Table 4-1 BMP2 application in cell based therapy 
Author Cell source Growth factor/Scaffold 
used 
Significance 
Chung et 
al100, 2007 
  
Critical size defect in rats. rhBMP-2- 200ng with 
Heparin functionalized 
nanoparticles in PLGA 
scaffold. 
 
Heparin nanoparticles with VEGF for 
bone formation. 
Luu et 
al101, 2006 
Pre-osteoblast 
progenitors cells. 
Adenoviral vectors 
express BMPs. 
BMP2, 6 and 9 are most osteogenic. 
 
Rickard et 
al102, 1993 
Rat marrow cells.  10-8 dexamethasone 
(dex), Vitamin D and 
BMP2. 
rhBMP2 and dex yield high ALP 
activity and increased osteoblastic 
mRNAs. 
Undifferentiated cells retain capacity 
to differentiate on further exposure to 
inducers. 
Fan et 
al103,2013 
Adipose derived stem 
cells of mice. 
 
Chitosan, chondroitin 
sulfate and apatite layer 
with controlled release 
of BMP2. 
Osteogenic induction with noggin 
suppression and addition of 
exogenous BMP2 . 
Alsberg104 
et al, 2002 
Cotransplantation of rat 
calvarial osteoblasts, 
bovine articular 
chondrocytes in SCID 
mice. 
MVG alginate hydrogel. Cotransplantation of cells with cell 
adhesion ligands to engineer bone 
tissue that grew by endochondral 
ossification similar to long- bone 
growth. 
Young et 
al105, 2009 
VEGF and BMP2. 
 
VEGF and BMP2 in 
Porous poly (propylene 
fumarate) scaffolds with 
gelatin microparticles. 
BMP2 has more sustained release 
profile compared to VEGF. 
Decreasing amounts of BMP2 while 
increasing levels of VEGF does not 
increase percentage bone formation 
significantly. 
VEGF- Vascular endothelial growth factor, SCID- Severe Combined Immunodeficiency, 
PLGA- Poly (lactic-co-glycolic acid). 
BMP2 is the leading osteoinductive growth factor used for bone regeneration currently. 
Table 4.1 lists several clinical applications of BMP2. The Food and Drug Administration 
has approved the use of INFUSE bone graft material for anterior and lumbar interbody 
fusion and open tibial fractures106,107. However, BMP2 use in supraphysiological doses 
for these clinical applications has resulted in adverse effects ranging from ectopic bone 
formation108, spinal cord impingement109, bone resorption110 and life threatening 
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cervical swelling65,111. Our aim was to find an optimum dose of BMP2, specifically for 
use in pediatric population.  
Our study showed that BMP2 significantly enhanced osteogenic differentiation of 
HUMSCs compared to osteogenic medium. At a concentration of 100ng/ml, a peak 
expression of ALP mRNA was noted. There was more than two fold increase in ALP 
mRNA expression with 100ng/ml but this increase showed a decline at 200ng/ml. 
However, there was no significant difference between the doses of 50ng/ml, 100ng/ml 
and 200ng/ml in terms of ALP mRNA expression. This suggests that lower doses of 
BMP2 are equally effective in enhancing osteogenic differentiation of HUMSCs. 
PuraMatrixTM as a scaffold promotes osteogenic regeneration112. Results from Hanada 
et al showed that at 50ng/ml concentration BMP2 treatment alone showed a slight 
increase in ALP activity in bone marrow stem cells, whereas the effect was significant 
when it was used in combination with Fibroblast growth factor (FGF)113. The high doses 
of BMP2 (20mg/ml) induced osteogenic differentiation in bone marrow cells of 
Beagle114. Recently, Zachos et al investigated the feasibility of using BMP2 in a 3 
dimensional model115. The results of the study indicated that BMP2 could be delivered 
using alginate as carrier system.  However, the results of previous studies 
demonstrated either high doses or use of BMP2 synergistically with other growth 
factors. In contrast, our results indicate that 1) BMP2 can induce osteogenic 
differentiation in presence of a 3D culture model 2) BMP2 enhanced osteogenic 
differentiation with concentrations as low as 50ng/ml. In summary, our results indicate 
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that minimal doses of BMP2 are sufficient when used in an appropriate 3D scaffold 
system.  
 Conclusion 4.2
PuraMatrixTM with HUMSCs and BMP2 is a viable composite system for osteogenic 
regeneration of bony defects. This composite system requires lower doses of BMP2 
thus minimizing potential adverse affects reported from using higher doses of BMP2. 
As this system is injectable into the in vivo site it will reduce the number of surgeries 
and the incidence of scar formation. Future research involves incorporating BMP2 
within the scaffold for site-specific delivery and to minimize its absorption systemically.  
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5 APPENDIX 
 
 
Figure 6-1 SAO Grant Award in support of this project. 
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6 RAW DATA  
 
Figure 6-1 ALP activity of HUMSCs in control CM and experimental group OM 
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Figure 6-2 Mean absorbance values of WST assay 
 
Figure 6-3 ALP activity of HUMSCs in PuraMatrixTM in BMP2 
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